Glimixia-VM1 Tablet ER is a combination oral antidiabetic medication formulated with Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, designed for extended-release administration. This triple-action formulation targets multiple pathophysiological defects in type 2 diabetes mellitus to achieve optimal glycemic control. Glimepiride, a sulfonylurea, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, improving insulin sensitivity without causing hypoglycemia. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, attenuating postprandial hyperglycemia. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Glimixia-VM1 is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus inadequately controlled by monotherapy or dual therapy. Caution is advised in patients with renal or hepatic impairment, and regular monitoring of blood glucose and renal function is recommended. This combination therapy should be used under medical supervision to optimize efficacy and minimize adverse effects.

Dosage & How to Use